Last $0.03 USD
Change Today -0.0078 / -20.10%
Volume 25.2K
As of 5:20 PM 07/10/14 All times are local (Market data is delayed by at least 15 minutes).

mymetics corp (MYMX) Snapshot

Open
$0.03
Previous Close
$0.04
Day High
$0.03
Day Low
$0.03
52 Week High
01/7/14 - $0.09
52 Week Low
08/6/13 - $0.01
Market Cap
9.4M
Average Volume 10 Days
2.0K
EPS TTM
$0.01
Shares Outstanding
303.8M
EX-Date
--
P/E TM
2.3x
Dividend
--
Dividend Yield
--
Current Stock Chart for MYMETICS CORP (MYMX)

Related News

No related news articles were found.

mymetics corp (MYMX) Related Businessweek News

No Related Businessweek News Found

mymetics corp (MYMX) Details

Mymetics Corporation, a vaccine company, develops vaccines that focus on the mucosal layer as a first line of defense against viruses entering the blood stream. The company also develops virosomes as a new vaccine delivery platform. Its product pipeline consists of five vaccines in development for the prevention and treatment of human immunodeficiency virus (HIV) type I, malaria, herpes simplex virus type I and II, respiratory syncytial virus, and intra-nasal influenza. The company was formerly known as Hippocampe S.A. and changed its name to Mymetics Corporation in July 2001. Mymetics Corporation was founded in 1990 and is based in Epalinges, Switzerland.

9 Employees
Last Reported Date: 05/14/14
Founded in 1990

mymetics corp (MYMX) Top Compensated Officers

Chief Executive Officer, President, Chief Ope...
Total Annual Compensation: €216.0K
Chief Scientific Officer
Total Annual Compensation: €216.0K
Compensation as of Fiscal Year 2013.

mymetics corp (MYMX) Key Developments

Mymetics Corporation Auditor Raises 'Going Concern' Doubt

Mymetics Corporation filed its 10-K on Mar 28, 2014 for the period ending Dec 31, 2013. In this report its auditor, Peterson Sullivan PLLC, gave an unqualified opinion expressing doubt that the company can continue as a going concern.

Mario Amacker Joins Mymetics as Head of Quality and Manufacturing

Mymetics announced that it has secured and further strengthened its know-how and leadership in the research and development of virosome based vaccines as well in manufacturing and IP. Dr. Mario Amacker recently joined Mymetics as Head of Quality and Manufacturing, after having been member of the executive management team and head of process development and manufacturing at Pevion Biotech SA. Dr. Amacker brings a wealth of experience and know-how in the manufacturing, formulation and quality aspects of influenza based virosomes and is a very strong addition to the Mymetics management team.

Astellas Announces In-Licensing of Vaccine for Respiratory Syncytial Virus from Mymetics Corp

Astellas has announced the in-licensing of a vaccine for respiratory syncytial virus (RSV) from Mymetics Corp. Astellas will pay Mymetics upfront and milestone payments of up to USD 82 million depending on the outcomes of that trial, as well as double-digit royalties on future sales. Astellas retains rights to acquire RSVC and carry out further development and commercialisation activities in the future.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MYMX:US $0.03 USD -0.0078

MYMX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for MYMX.
View Industry Companies
 

Industry Analysis

MYMX

Industry Average

Valuation MYMX Industry Range
Price/Earnings 100.0x
Price/Sales 1.7x
Price/Book NM Not Meaningful
Price/Cash Flow 138.0x
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MYMETICS CORP, please visit www.mymetics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.